Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies

BACKGROUND: KW-2478 is a novel, non-ansamycin, non-purine heat-shock protein 90 (Hsp90) inhibitor. METHODS: In this phase I, multicentre study, KW-2478 was administered intravenously over 1 h at doses ranging from 14 to 176 mg m(–2) once daily on days 1–5 of a 14-day cycle in a standard 3+3 design i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yong, K, Cavet, J, Johnson, P, Morgan, G, Williams, C, Nakashima, D, Akinaga, S, Oakervee, H, Cavenagh, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716540/
https://www.ncbi.nlm.nih.gov/pubmed/26695442
http://dx.doi.org/10.1038/bjc.2015.422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716540/
https://www.ncbi.nlm.nih.gov/pubmed/26695442
http://dx.doi.org/10.1038/bjc.2015.422

Ejemplares similares